# Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

> **NCT02179671** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** AZD9291
- **DRUG:** Selumetinib+Docetaxel
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT02179671
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-25
- **Primary completion:** 2016-06-11
- **Final completion:** 2016-06-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02179671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02179671, "Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02179671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*